Show simple item record

dc.contributor.authorGregory, AE
dc.contributor.authorTitball, R
dc.contributor.authorWilliamson, D
dc.date.accessioned2016-11-28T11:16:43Z
dc.date.issued2013
dc.description.abstractVaccination has had a major impact on the control of infectious diseases. However, there are still many infectious diseases for which the development of an effective vaccine has been elusive. In many cases the failure to devise vaccines is a consequence of the inability of vaccine candidates to evoke appropriate immune responses. This is especially true where cellular immunity is required for protective immunity and this problem is compounded by the move toward devising sub-unit vaccines. Over the past decade nanoscale size (<1000 nm) materials such as virus-like particles, liposomes, ISCOMs, polymeric, and non-degradable nanospheres have received attention as potential delivery vehicles for vaccine antigens which can both stabilize vaccine antigens and act as adjuvants. Importantly, some of these nanoparticles (NPs) are able to enter antigen-presenting cells by different pathways, thereby modulating the immune response to the antigen. This may be critical for the induction of protective Th1-type immune responses to intracellular pathogens. Their properties also make them suitable for the delivery of antigens at mucosal surfaces and for intradermal administration. In this review we compare the utilities of different NP systems for the delivery of sub-unit vaccines and evaluate the potential of these delivery systems for the development of new vaccines against a range of pathogens.en_GB
dc.description.sponsorshipThis work was partly supported by grant number U54 AI057156 from the Western Regional Centre for Excellence, USA. The study performed in the laboratory of RWT was supported by NIH/NIAID grant U54 AI057156 from the Western Regional Center for Excellence. The contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIAID or NIH.en_GB
dc.identifier.citationVol 3:13. doi: 10.3389/fcimb.2013.00013.en_GB
dc.identifier.doi10.3389/fcimb.2013.00013
dc.identifier.urihttp://hdl.handle.net/10871/24615
dc.language.isoenen_GB
dc.publisherFrontiers Mediaen_GB
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pubmed/23532930en_GB
dc.rightsThis Document is Protected by copyright and was first published by Frontiers. All rights reserved. it is reproduced with permission.en_GB
dc.subjectadjuvanten_GB
dc.subjectantigen-presenting cellen_GB
dc.subjectimmunityen_GB
dc.subjectnanoparticleen_GB
dc.subjectvaccineen_GB
dc.subjectAntigen-Presenting Cellsen_GB
dc.subjectDrug Carriersen_GB
dc.subjectImmunity, Cellularen_GB
dc.subjectNanoparticlesen_GB
dc.subjectTh1 Cellsen_GB
dc.subjectVaccines, Subuniten_GB
dc.titleVaccine delivery using nanoparticlesen_GB
dc.typeArticleen_GB
dc.date.available2016-11-28T11:16:43Z
dc.identifier.issn2235-2988
exeter.place-of-publicationSwitzerlanden_GB
dc.descriptionThis is the final version of the article. Available from the publisher via the DOI in this record.en_GB
dc.identifier.journalFrontiers in Cellular and Infection Microbiologyen_GB
dc.identifier.pmcidPMC3607064
dc.identifier.pmid23532930


Files in this item

This item appears in the following Collection(s)

Show simple item record